RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors — NEJM

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors — NEJM

BRAF inhibitors are gaining increasing attention for treatment of BRAF mutated cancers. A proportion of patients develop squamous cell carcinoma. A possible mechanism is identified here: RAS mutation can account for this in a substantial proportion of those patients.